Mon . 20 Jul 2020
TR | RU | UK | KK | BE |

Pseudobulbar affect

pseudo bulbar affect, pseudo bulbar affective disorder
Pseudobulbar affect PBA, or emotional incontinence, is a type of affect characterized by involuntary crying or uncontrollable episodes of crying and/or laughing, or other emotional displays PBA occurs secondary to a neurologic disorder or brain injury Patients may find themselves crying uncontrollably at something that is only moderately sad, being unable to stop themselves for several minutes Episodes may also be mood-incongruent: a patient may laugh uncontrollably when angry or frustrated, for example Sometimes, the episodes may switch between emotional states, resulting in the patient crying uncontrollably when having sex

While typically caused by physiological damage or disorder, emotional lability is known to accompany certain personality disorders, such as borderline personality disorder1

Contents

  • 1 Terminology
  • 2 Signs and symptoms
    • 21 Social impact
    • 22 Depression
  • 3 Causes
    • 31 Secondary condition
    • 32 Stroke
    • 33 Multiple sclerosis
    • 34 Amyotrophic lateral sclerosis
    • 35 Traumatic brain injury
  • 4 Treatment
    • 41 Dextromethorphan/quinidine
  • 5 Epidemiology
  • 6 History
  • 7 See also
  • 8 References
  • 9 External links

Terminologyedit

Historically, there have been a variety of terms used for the disorder, including pseudobulbar affect, pathological laughter and crying, emotional lability, emotionalism, emotional dysregulation, or more recently, involuntary emotional expression disorder2 The term pseudobulbar pseudo- + bulbar came from the idea that the symptoms seemed similar to those caused by a bulbar lesion that is, a lesion in the medulla oblongata

Terms such as forced crying, involuntary crying, pathological emotionality, and emotional incontinence have also been used, although less frequently3

Signs and symptomsedit

The cardinal feature of the disorder is a pathologically lowered threshold for exhibiting the behavioral response of laughter, crying, or both An affected individual exhibits episodes of laughter and/or crying without an apparent motivating stimulus or in response to stimuli that would not have elicited such an emotional response before the onset of their underlying neurologic disorder In some patients, the emotional response is exaggerated in intensity but is provoked by a stimulus with an emotional valence congruent with the character of the emotional display For example, a sad stimulus provokes a pathologically exaggerated weeping response instead of a sigh, which the patient normally would have exhibited in that particular instance

However, in some other patients, the character of the emotional display can be incongruent with, and even contradictory to, the emotional valence of the provoking stimulus or may be incited by a stimulus with no clear valence For example, a patient may laugh in response to sad news or cry in response to stimuli with no emotional undertone, or, once provoked, the episodes may switch from laughing to crying or vice versa4

The symptoms of PBA can be severe, with persistent and unremitting episodes3 Characteristics include:

  • The onset can be sudden and unpredictable, and has been described by some patients as coming on like a seizure;
  • The outbursts have a typical duration of a few seconds to several minutes; and,
  • The outbursts may happen several times a day

Many people with neurologic disorders exhibit uncontrollable episodes of laughing, crying, or both that are either exaggerated or contradictory to the context in which they occur Where patients have significant cognitive deficits eg, Alzheimer's it can be unclear whether it is true PBA as opposed to a grosser form of emotional dysregulation, but patients with intact cognition often report the symptom as disturbing Patients report that their episodes are at best only partially amenable to voluntary control, and unless they experience a severe change of mental status, they often have insight into their problem and judge their emotional display as inappropriate and out of character The clinical effect of PBA can be severe, with unremitting and persistent symptoms that can be disabling to patients, and may significantly affect quality of life for caregivers

Social impactedit

While not as profoundly disabling as the physical symptoms of these diseases, PBA can significantly influence individuals' social functioning and their relationships with others Such sudden, frequent, extreme, uncontrollable emotional outbursts may lead to social withdrawal and interfere with activities of daily living, social and professional pursuits, and reduce overall healthcare For example, patients with ALS and MS are often cognitively normal However, the appearance of uncontrollable emotions is commonly associated with many additional neurological disorders such as attention deficit/hyperactivity disorder,5 Parkinson's disease,6 cerebral palsy,7 autism,8 epilepsy,9 and migraines10 This may lead to severe embarrassment and avoidance of social interactions for the patient, which in turn impairs their coping mechanisms and their careers311121314

Several criteria exist to differentiate between PBA and depression

Depressionedit

PBA may often be misdiagnosed as clinical depression; however, many clear distinctions exist

In depression and grief syndromes, crying is typically a sign of sadness, whereas the pathological displays of crying which occur in PBA are often in contrast to the underlying mood, or greatly in excess of the mood or eliciting stimulus In addition, a key to differentiating depression from PBA is duration: PBA episodes are sudden, occurring in a brief episodic manner, while crying in depression is a more sustained presentation and closely relates to the underlying mood state The level of control that one has over the crying episodes in PBA is minimal or nonexistent, whereas for those suffering from depression, the emotional expression typically crying can be modulated by the situation Similarly, the trigger for episodes of crying in patients with PBA may be nonspecific, minimal or inappropriate to the situation, but in depression the stimulus is specific to the mood-related condition These differences are outlined in the adjacent Table

In some cases, depressed mood and PBA may co-exist In fact, depression is one of the most common emotional changes in patients with neurodegenerative disease or post-stroke sequelae As a result, it is often comorbid with PBA Comorbidity implies that depression is distinct from PBA and is not necessary for, nor does it exclude, a diagnosis of PBA2

Causesedit

The specific pathophysiology involved in this frequently debilitating condition is still under investigation; the primary pathogenic mechanisms of PBA remain controversial15 One hypothesis, established by early researchers such as Wilson and Oppenheim, placed emphasis on the role of the corticobulbar pathways in modulating emotional expression in a top-down model, and theorized that PBA occurs when bilateral lesions in the descending corticobulbar tract cause failure of voluntary control of emotion, which leads to the disinhibition, or release, of laughing/crying centers in the brainstem16 Other theories implicate the prefrontal cortex17

Secondary conditionedit

Pseudobulbar affect is a condition that occurs secondary to neurological disease or brain injury, and is thought to result from disruptions of neural networks that control the generation and regulation of motor output of emotions PBA is most commonly observed in people with neurologic injuries such as traumatic brain injury TBI and stroke,1618 and neurologic diseases such as dementias including Alzheimer's disease, attention deficit/hyperactivity disorder ADHD,519 multiple sclerosis MS, amyotrophic lateral sclerosis ALS, Lyme disease, PANDAS in children and adults, and Parkinson's disease PD It has been reported as a symptom of hyperthyroidism, Graves' Disease, or hypothyroidism in combination with depression20

PBA has also been observed in association with a variety of other brain disorders, including brain tumors, Wilson's disease, syphilitic pseudobulbar palsy, and various encephalitides Rarer conditions associated with PBA include gelastic epilepsy, dacrystic epilepsy, central pontine myelinolysis, olivopontinocerebellar atrophy, lipid storage diseases, chemical exposure eg, nitrous oxide and insecticides, fou rire prodromique, and Angelman syndrome

It is hypothesized that these primary neurologic injuries and diseases affect chemical signaling in the brain, which in turn disrupts the neurologic pathways that control emotional expression212223

Strokeedit

PBA is one of the most frequently reported post-stroke behavioral syndromes, with a range of reported prevalence rates from 28% to 52%242526 The higher prevalence rates tend to be reported in stroke patients who are older and/or who have a history of prior stroke2728 The relationship between post-stroke depression and PBA is complicated, because the depressive syndrome also occurs with high frequency in stroke survivors Post-stroke patients with PBA are more depressed than poststroke patients without PBA, and the presence of a depressive syndrome may exacerbate the weeping side of PBA symptoms2429

Multiple sclerosisedit

Recent studies suggest that approximately 10% of patients with multiple sclerosis MS will experience at least one episode of emotional lability3031 PBA is generally associated with later stages of the disease chronic progressive phase26 PBA in MS patients is associated with more severe intellectual deterioration, physical disability, and neurological disability32

Amyotrophic lateral sclerosisedit

A study designed specifically to survey for prevalence found that 49% of patients with amyotrophic lateral sclerosis ALS also had PBA11 PBA does not appear to be associated with duration of ALS3334 It is a symptom of ALS that many patients are unaware of and do not receive information about from their physician35

Traumatic brain injuryedit

One study of 301 consecutive cases in a clinic setting reported a 5% prevalence PBA occurred in patients with more severe head injury, and coincided with other neurological features suggestive of pseudobulbar palsy36

The Brain Injury Association of America BIAA indicates that approximately 80% of survey respondents experience symptoms of PBA37 Results from a recent investigation estimate the prevalence of PBA associated with traumatic brain injury to exceed more than 55% of survivors38

Treatmentedit

Education of patients, families, and caregivers is an important component of the appropriate treatment of PBA Crying associated with PBA may be incorrectly interpreted as depression; laughter may be embarrassing It is therefore critical for families and caregivers to recognize the pathological nature of PBA and the reassurance that this is an involuntary syndrome that is manageable Traditionally, antidepressants such as sertraline,39 fluoxetine,40citalopram,41 nortriptyline42 and amitriptyline43 have been prescribed with some efficacy

Dextromethorphan/quinidineedit

Dextromethorphan hydrobromide is a generic drug that affects the signals in the brain that trigger the cough reflex It is generally used as a cough suppressant, although it can sometimes be used, medicinally, as a pain reliever, and is also used as a recreational drug44 "Dextromethorphan DM is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist"45

Quinidine sulfate affects the way the heart beats, and is generally used in people with certain heart rhythm disorders It is also used to treat malaria46 Quinidine sulfate, as a metabolic inhibitor, "increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan," enabling therapeutic dextromethorphan concentrations4547

Nuedexta is a patented combination of these two generic drugs, and is the first FDA-approved drug for the treatment of PBA, approved on October 29, 201048 In December 2007, clinical study information for Nuedexta was first submitted to ClinicalTrialsgov, a Web-based resource maintained by the National Library of Medicine NLM at the National Institutes of Health NIH Sponsored by Avanir Pharmaceuticals, with brief title, Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS, the study was assigned NCT Number NCT00573443 Final updates and verifications occurred in June 2013 on the ClinicalTrialsgov site49

For this multicenter study, the "Objectiveswere to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 Dextromethorphan/quinidine combinationwhen compared to placebo"49 The conditions and results of that study are as follows:

At one study site, a total of 326 participants received one of three dose options "METHODS: In a 12-week randomized, double-blind trial, ALS and MS patients with clinically significant PBA" were given a twice-daily dose of one of the following:

  • placebo N=109
  • dextromethorphan hydrobromide 30 mg/quinidine sulfate 10 mg N=110
  • Nuedexta – dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg N=107

283 patients 868% completed the study The number of PBA episodes laughing and crying were 47% and 49% lower based on the trial's outcome measures, respectively, for the drug-combination options than for the placebo The "mean CNS-LS scores" decreased by 82 points for both drug-combination options, vs a decrease of 57 points for the placebo Overall, the trial showed a statistically significant benefit from taking a combination of Dextromethorphan and quinidine, with both dosages being safe and well tolerated For a secondary objective measuring a participant's "perceived health statusmeasuring eight health concepts: vitality, physical functioning, bodily pain, general health perceptions, physical role-, emotional role-, social role functioning, and mental health," the higher dosage showed improvement, especially on measures of social functioning and mental health4950

Other studies have confirmed the results of NCT00573443, but, "The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown"45

Epidemiologyedit

Prevalence estimates place the number of people with PBA between 15 and 2 million in the United States alone, which would be less than 1% of the US population even at the high end of the estimate Some argue that the number is probably higher and that clinicians underdiagnose PBA51 However, the prevalence estimate of 2 million is based on an online survey Self-selected computer-savvy patients in at-risk groups evaluated their own symptoms and submitted their self-diagnoses No doctor or clinic confirmed the data Motivation to participate could have been influenced by the presence of symptoms, which would have skewed the results The actual prevalence could very well be quite a bit lower than estimated52

Historyedit

The Expression of the Emotions in Man and Animals by Charles Darwin was published in 187253 In Chapter VI, "Special Expressions of Man: Suffering and Weeping", Darwin discusses cultural variations in the acceptability of weeping and the wide differences in individual responses to suffering The chapter contains the following sentence:

We must not, however, lay too much stress on the copious shedding of tears by the insane, as being due to the lack of all restraint; for certain brain-diseases, as hemiplegia, brain-wasting, and senile decay, have a special tendency to induce weeping54

See alsoedit

  • Affect psychology
  • Affect display

Referencesedit

  1. ^ mentalhealthcom/home/dx/borderlinepersonalityhtml
  2. ^ a b Cummings J, Arciniegas D, Brooks B, Herndon R, Lauterbach E, Pioro E, Robinson R, Scharre D, Schiffer R, Weintraub D; Arciniegas; Brooks; Herndon; Lauterbach; Pioro; Robinson; Scharre; Schiffer; Weintraub 2006 "Defining and diagnosing involuntary emotional expression disorder" CNS Spectrums 11 6: 1–7 PMID 16816786 CS1 maint: Multiple names: authors list link
  3. ^ a b c Dark FL, McGrath JJ, Ron MA; McGrath; Ron 1996 "Pathological laughing and crying" Australian and New Zealand Journal of Psychiatry 30 4: 472–479 PMID 8887697 doi:103109/00048679609065020 CS1 maint: Multiple names: authors list link
  4. ^ Parvizi J, Archiniegas DB, Bernardini GL, Hoffman MW, et al 2006 "Diagnosis and management of pathological laughter and crying" Mayo Clinic Proceedings 81 11: 1482–1486 PMID 17120404 doi:104065/81111482 
  5. ^ a b Skirrow, Caroline; Asherson, Philip 2013 "Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder" Journal of Affective Disorders 147 1–3: 80–6 PMID 23218897 doi:101016/jjad201210011 
  6. ^ Latoo, Javed; Mistry, Minal; Dunne, Francis J 2013 "Often overlooked neuropsychiatric syndromes in Parkinson's disease" British Journal of Medical Practitioners 6 1 Retrieved 4 November 2014 
  7. ^ Levitt, S 2013 Treatment of Cerebral Palsy and Motor Delay Wiley ISBN 9781118699782 Retrieved 4 November 2014 
  8. ^ Atchison, B; Dirette, DK 2007 Conditions in Occupational Therapy: Effect on Occupational Performance Lippincott Williams & Wilkins p 40 ISBN 9780781754873 Retrieved 4 November 2014 
  9. ^ Devinsky, O; Vazquez, B 1993 "Behavioral changes associated with epilepsy" Neurological Clinics 11 1: 127–49 PMID 8441366 
  10. ^ "Medscape: Medscape Access" medscapecom Retrieved 4 November 2014 
  11. ^ a b Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA; Gresham; Bromberg; Kasarkis; Smith 1997 "A self report measure of affective lability" Journal of Neurology, Neurosurgery, and Psychiatry 63 1: 89–93 PMC 2169647  PMID 9221973 doi:101136/jnnp63189 CS1 maint: Multiple names: authors list link
  12. ^ Shaibani AT, Sabbagh MN, Doody R 1994 "Laughter and crying in neurologic disorders" Neuropsychiatry, Neuropsychology, and Behavioral Neurology 7: 243–250 
  13. ^ Black DW 1982 "Pathological laughter A review of the literature" Journal of Nervous and Mental Disease 170 2: 67–71 PMID 7057172 doi:101097/00005053-198202000-00001 
  14. ^ Green RL 1998 "Regulation of affect" Seminars in Clinical Neuropsychiatry 3 3: 195–200 PMID 10085207 
  15. ^ Archiniegas DB, Topkoff J 2000 "The neuropsychiatry of pathologic affect: an approach to evaluation and treatment" Seminars in Clinical Neuropsychiatry 5 4: 290–306 PMID 11291026 doi:101053/scnp20009554 
  16. ^ a b Parvizi J, Anderson SW, Martin CO, Damasio H, Damasio AR; Anderson; Martin; Damasio; Damasio 2001 "Pathological laughter and crying: a link to the cerebellum" Brain 124 Pt 9: 1708–1719 PMID 11522574 doi:101093/brain/12491708 CS1 maint: Multiple names: authors list link
  17. ^ McCullagh S, Moore M, Gawel M, Feinstein A 1999 "Pathological laughing and crying in amyotrophic lateral sclerosis: an association with prefrontal cognitive dysfunction" Journal of the Neurological Sciences 169: 43–48 doi:101016/s0022-510x9900214-2 
  18. ^ Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR; Parikh; Lipsey; Starkstein; Price 1993 "Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study" American Journal of Psychiatry 150 2: 286–293 PMID 8422080 doi:101176/ajp1502286 CS1 maint: Multiple names: authors list link
  19. ^ Lopez, Oscar L; Gonzalez, Maria P; Becker, James T; Reynolds, Charles F; Sudilovsky, Abraham; DeKosky, Steven T 1996 "Symptoms of depression and psychosis in Alzheimer's disease and frontotemporal dementia: exploration of underlying mechanisms" Neuropsychiatry, Neuropsychology, and Behavioral Neurology 9 3: 154–161 
  20. ^ Tremont Geogffery "Neurbehavioral Functioning in Thyroid Disorders" Medicine and Health http://medbrownedu/neurology/articles/gt31803pdf
  21. ^ Greenamyre JT 1986 "The role of glutamate in neurotransmission and in neurologic disease" Archives of Neurology 43 10: 1058–1063 PMID 2428340 doi:101001/archneur198600520100062016 
  22. ^ Bittigau P, Ikonomidou C; Ikonomidou 1997 "Glutamate in neurologic diseases" Journal of Child Neurology 12 8: 461–485 PMID 9430311 doi:101177/088307389701200802 
  23. ^ Mattson MP 2003 "Excitotoxic and excitoprotective mechanism: abundant targets for the prevention and treatment of neurodegenerative disorders" Neuromolecular Medicine 3 2: 65–94 PMID 12728191 doi:101385/NMM:3:2:65 
  24. ^ a b House A, Dennis M, Molyneux A, Warlow C, Hawton K; Dennis; Molyneux; Warlow; Hawton 1989 "Emotionalism after stroke" BMJ 298 6679: 991–994 PMC 1836312  PMID 2499390 doi:101136/bmj2986679991 CS1 maint: Multiple names: authors list link
  25. ^ Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K; Hornstein; Flax; Herbert; Schroeder 1992 "Fluoxetine improves emotional incontinence" Brain Injury 6 3: 267–270 PMID 1581749 doi:103109/02699059209029668 CS1 maint: Multiple names: authors list link
  26. ^ a b Feinstein A, Feinstein K, Gray T, O'Connor P; Feinstein; Gray; O'Connor 1997 "Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis" Archives of Neurology 54 9: 1116–1121 PMID 9311355 doi:101001/archneur199700550210050012 CS1 maint: Multiple names: authors list link
  27. ^ Kim JS 2002 "Post-stroke emotional incontinence after small lenticulocapsular stroke: correlation with lesion location" Journal of Neurology 249 7: 805–810 PMID 12140660 doi:101007/s00415-002-0714-4 
  28. ^ Harris Y, Gorelick PB, Cohen D, Dollear W, et al 1994 "Psychiatric symptoms in dementia associated with stroke: a case-control analysis among predominantly African-American patients" Journal of the National Medical Association 86 9: 697–702 PMC 2607578  PMID 7966434 
  29. ^ Ross ED, Stewart RS; Stewart 1987 "Pathological display of affect in patients with depression and right frontal brain damage An alternative mechanism" Journal of Nervous and Mental Disease 175 3: 165–172 PMID 3819712 doi:101097/00005053-198703000-00007 
  30. ^ Haupt 1996 "Emotional lability, intrusiveness, and catastrophic reactions" International Psychogeriatrics 8 Suppl 3: 409–414 PMID 9154598 doi:101017/S1041610297003736 
  31. ^ Sloan RL, Brown KW, Pentland B; Brown; Pentland 1992 "Fluoxetine as a treatment for emotional lability after brain injury" Brain Injury 6 4: 315–319 PMID 1638265 doi:103109/02699059209034945 CS1 maint: Multiple names: authors list link
  32. ^ Surridge D 1969 "An investigation into some psychiatric aspects of multiple sclerosis" British Journal of Psychiatry 115 524: 749–764 PMID 5806869 doi:101192/bjp115524749 
  33. ^ Caroscio JT, Mulvihill MN, Sterling R, Abrams B; Mulvihill; Sterling; Abrams 1987 "Amyotrophic lateral sclerosis" Neurological Clinics 5 1: 1–8 PMID 3561382 CS1 maint: Multiple names: authors list link
  34. ^ Gallagher JP 1989 "Pathologic laughter and crying in ALS: a search for their origin" Acta Neurologica Scandinavica 80 2: 114–117 PMID 2816272 doi:101111/j1600-04041989tb03851x 
  35. ^ Wicks P Frost J; Frost 2008 "ALS patients request more information about cognitive symptoms" European Journal of Neurology 15 5: 497–500 PMID 18325023 doi:101111/j1468-1331200802107x 
  36. ^ Zeilig G, Drubach DA, Katz-Zeilig M, Karatinos J; Drubach; Katz-Zeilig; Karatinos 1996 "Pathological laughter and crying in patients with closed traumatic brain injury" Brain Injury 10 8: 591–597 PMID 8836516 doi:101080/026990596124160 CS1 maint: Multiple names: authors list link
  37. ^ http://wwwbiausaorg/_literature_77385/1-7-2011_PBA_Survey_Resultsfull citation needed
  38. ^ Fellus JL, Kantor D, Kaye RE 2012 "PRISM registry: A novel research tool to determine the prevalence of pseudobulbar affect" European Journal of Neurology 19 S1: 85–90 doi:101111/j1468-1331201203887x 
  39. ^ Burns, Alistair; Russell, Eve; Stratton-Powell, Hilary; Tyrell, Pippa; O'Neill, Paul; Baldwin, Robert 1999 "Sertraline in stroke-associated lability of mood" International Journal of Geriatric Psychiatry 14 8: 681–5 PMID 10489659 doi:101002/SICI1099-116619990814:8<681::AID-GPS49>30CO;2-Z 
  40. ^ Brown, K W; Sloan, R L; Pentland, B 1998 "Fluoxetine as a treatment for post-stroke emotionalism" Acta Psychiatrica Scandinavica 98 6: 455–8 PMID 9879787 doi:101111/j1600-04471998tb10119x 
  41. ^ Andersen, G; Vestergaard, K; Riis, J O 1993 "Citalopram for post-stroke pathological crying" The Lancet 342 8875: 837–9 PMID 8104273 doi:101016/0140-67369392696-Q 
  42. ^ Robinson, RG; Parikh, RM; Lipsey, JR; Starkstein, SE; Price, TR 1993 "Pathological laughing and crying following stroke: Validation of a measurement scale and a double-blind treatment study" American Journal of Psychiatry 150 2: 286–93 PMID 8422080 doi:101176/ajp1502286 
  43. ^ Schiffer, Randolph B; Herndon, Robert M; Rudick, Richard A 1985 "Treatment of Pathologic Laughing and Weeping with Amitriptyline" The New England Journal of Medicine 312 23: 1480–2 PMID 3887172 doi:101056/NEJM198506063122303 
  44. ^ "Dextromethorphan DXM" Cesarumdedu Retrieved 2016-02-18 
  45. ^ a b c "Label: NUEDEXTA- dextromethorphan hydrobromide and quinidine sulfate capsule, gelatin coated" US National Library of Medicine, DailyMed 2015-01-30 Retrieved 2016-02-18 
  46. ^ "Quinidine sulfate" PDRhealth™ 2016 Retrieved 2016-02-18 
  47. ^ "Avanir Pharmaceuticals : Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference" PR Newswire 2015-07-23 Retrieved 2016-02-18 
  48. ^ "Nuedexta, FDA Approval History" Drugscom January 2015 Retrieved 2016-02-18 
  49. ^ a b c "Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS STAR" ClinicalTrialsgov June 2013 Retrieved 2016-02-19 
  50. ^ Pioro, Erik P; Brooks, Benjamin Rix; Cummings, Jeffrey; Schiffer, Randolph; Thisted, Ronald A; Wynn, Daniel; Hepner, Adrian; Kaye, Randall 2010 "Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect" Annals of Neurology 68 5: 693–702 PMID 20839238 doi:101002/ana22093 
  51. ^ Archiniegas DB, Lauterbach EC, Anderson KE, Chow TW, et al 2005 "The differential diagnosis of pseudobulbar affect PBA Distinguishing PBA among disorders of mood and affect Proceedings of a roundtable meeting" CNS Spectrums 10 5: 1–16 PMID 15962457 
  52. ^ Brooks, Benjamin Rix; Crumpacker, David; Fellus, Jonathan; Kantor, Daniel; Kaye, Randall E Aug 21, 2013 "PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions" PLOS ONE Public Library of Science 8 8: e72232 PMC 3749118  PMID 23991068 doi:101371/journalpone0072232 
  53. ^ http://darwin-onlineorguk/content/framesetpageseq=1&itemID=F1142&viewtype=text
  54. ^ p 156 http://darwin-onlineorguk/content/framesetpageseq=1&itemID=F1142&viewtype=text

External linksedit

  • "Pseudobulbar affect and stroke" on the National Stroke Association website

pseudo bulbar affect, pseudo bulbar affect causes, pseudo bulbar affect commercial, pseudo bulbar affect diagnostic criteria, pseudo bulbar affect icd 10, pseudo bulbar affect medication, pseudo bulbar affect symptoms, pseudo bulbar affect treatment, pseudo bulbar affect vs depression chart, pseudo bulbar affective disorder


Pseudobulbar affect Information about

Pseudobulbar affect


  • user icon

    Pseudobulbar affect beatiful post thanks!

    29.10.2014


Pseudobulbar affect
Pseudobulbar affect
Pseudobulbar affect viewing the topic.
Pseudobulbar affect what, Pseudobulbar affect who, Pseudobulbar affect explanation

There are excerpts from wikipedia on this article and video

Random Posts

Book

Book

A book is a set of written, printed, illustrated, or blank sheets, made of ink, paper, parchment, or...
Boston Renegades

Boston Renegades

Boston Renegades was an American women’s soccer team, founded in 2003 The team was a member of the U...
Sa Caleta Phoenician Settlement

Sa Caleta Phoenician Settlement

Sa Caleta Phoenician Settlement can be found on a rocky headland about 10 kilometers west of Ibiza T...
Bodybuilding.com

Bodybuilding.com

Bodybuildingcom is an American online retailer based in Boise, Idaho, specializing in dietary supple...